Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 12, Pages 2601-2607
Publisher
Springer Nature
Online
2017-05-02
DOI
10.1038/leu.2017.129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-4 enhances expression and function of surface IgM in CLL cells
- (2016) M. M. Aguilar-Hernandez et al. BLOOD
- Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia
- (2015) M. Wagner et al. BLOOD
- Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
- (2015) M. F. M. de Rooij et al. BLOOD
- TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells
- (2015) Patricia K. A. Mongini et al. JOURNAL OF IMMUNOLOGY
- The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
- (2015) R Thijssen et al. LEUKEMIA
- Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
- (2015) Ailin Guo et al. Oncotarget
- Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo
- (2015) Noelia Purroy et al. Oncotarget
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
- (2014) S E M Herman et al. LEUKEMIA
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
- (2014) A. Wiestner Hematology-American Society of Hematology Education Program
- IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells
- (2013) M. F. Pascutti et al. BLOOD
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
- (2013) G. Yang et al. BLOOD
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
- (2013) B. Y. Chang et al. BLOOD
- MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
- (2013) L. Xu et al. BLOOD
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
- (2012) Marcus Dühren-von Minden et al. NATURE
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2011) Takuro Igawa et al. CANCER SCIENCE
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
- (2010) A Scuto et al. LEUKEMIA
- Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering
- (2010) J M Tromp et al. ONCOGENE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TRAF6 deficiency promotes TNF-induced cell death through inactivation of GSK3β
- (2008) K Yoon et al. CELL DEATH AND DIFFERENTIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation